Afterpay continues its rise

Published 27-AUG-2018 15:45 P.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Buy-now pay later leader, Afterpay Group (ASX:APT) is off to a strong start this week, with its shares up as much as 8.8% this morning.

This optimism follows last week’s share price gain of 18.5%. That rally came as the group successfully completed a $117 capital raising to support its international expansion, announced it was entering the UK market via the purchase of Clearpay, and reported its financial year results.

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

International expansion

On Thursday, the payments company announced that it is expanding into the UK market, buying UK payments business ClearPay — an entity 100% owned by ThinkSmart — that has an established operational footprint in the UK.

ClearPay enables customers to purchase items up to £450 in value and make repayments in three interest-free monthly instalments.

The move position APT in one of the world’s largest consumer retail markets and follows its successful launch into the US market earlier this year, which logged approximately A$20 million of underlying sales processed in July 2018.

Institutions take note

APT has been a retail investor favourite over the past year, with retail brokers largely behind the impressive share price rally. This has left many fund managers underweight the stock and — especially now that the company has entered the ASX 200 index — institutional funds are rushing to play catch up and rebalance.

Institutions are reported to have taken a large chunk of last week’s capital raising, even with the placement priced at $17.05 — the top end of the placement price range with an underwritten floor price of $15.75 per share.

The raising was well received and oversubscribed with “several additional high-quality institutions” welcomed to the register. The group indicated that it will be followed up with APT aiming to raise a further $20 million through a share purchase plan for existing retail investors.

Financial results

While still to report a profit, Afterpay was able to reduce its net loss this year while continuing to drive its international expansion strategy. The company’s net loss reduced by 6% over the year to $9 million. This improvement comes down to a “significant increase” in the number of retailers signing up to its payment platform and greater customer adoption of the platform as a payment method and budget tool.

This came as revenue rose by 397% to $113.9 million. Underlying sales were up 289% on the prior financial year, at $2.18 billion, driven by growth across all key demand drivers — new customers, repeat customer activity, new retailers, increased share of checkout.

While 95% of payments received didn’t incur a late fee, income earned from late fees did make up almost a quarter its income for the year, with 75.6% coming from commission fees charged to retailers for each sale.

As mentioned in the last Finfeed article, one risk to the business is that it will come under greater scrutiny of financial regulators. It currently operates outside of consumer credit laws, but legislation looks likely to change so that late fees would come under greater scrutiny.

Interestingly it earns 24% of its income from late fees, a figure that has surged 365% to $28.4 million as reported in its latest annual report last week.

One accusation levelled against it is that customers are able to continue to use the system even after they are overdue on a payment.

However an Afterpay spokesperson told ABC News: "Customers cannot continue to use the system if they are overdue on any payment.

"94 per cent of Afterpay transactions are from returning customers, which means they do not have any overdue amounts.

"Afterpay purchases do not affect credit ratings as we do not report to the credit-rating agencies."

The Australian Securities and Investment Commission (ASIC) is now looking to close the loophole whereby buy now, pay later companies are not currently covered by the National Credit Code and are therefore unregulated.

“This article is General Information and contains only some information about some elements of one or more financial products. It may contain; (1) broker projections and price targets that are only estimates and may not be met, (2) historical data in terms of earnings performance and/or share trading patterns that should not be used as the basis for an investment as they may or may not be replicated. Those considering engaging with any financial product mentioned in this article should always seek independent financial advice from a licensed financial advisor before making any financial decisions.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X